Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

Most recent public disclosures: AI-powered summaries of the latest corporate filings

251
1
Reborn Coffee, Inc. Reborn Coffee Reports $5.93 Million Revenue with 7.6% Growth and $4.81 Million Net Loss for 2024

Via official filing (AI summary) | 11 days ago | 0 comments

252
1
Metal Sky Star Acquisition Corp Metal Sky Star Acquisition Corporation Reports Working Capital Deficit and Decreased Net Income

Via official filing (AI summary) | 11 days ago | 0 comments

253
1
Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Regenerative Technology Reports 2024 Financial Results with Revenue Growth and Operating Losses

Via official filing (AI summary) | 11 days ago | 0 comments

254
1
VOLITIONRX LTD VolitionRx Reports 59% Revenue Growth to $1.23 Million for Fiscal Year 2024

Via official filing (AI summary) | 11 days ago | 0 comments

255
1
OMEROS CORP Omeros Corporation Reports $156.8 Million Net Loss for 2024, Focuses on Product Pipeline

Via official filing (AI summary) | 11 days ago | 0 comments

256
1
Oak Valley Bancorp Oak Valley Bancorp Reports 3.2% Asset Growth, Net Income Decline in 2024

Via official filing (AI summary) | 11 days ago | 0 comments

257
1
EAGLE FINANCIAL SERVICES INC Eagle Financial Services Reports 63.97% Increase in Net Income for Fiscal Year 2024

Via official filing (AI summary) | 11 days ago | 0 comments

258
1
STRATS SM TRUST FOR U S CELL CORP SEC SERIES 2004 6 Synthetic Fixed-Income Securities, Inc. Files 10-K for STRATS Trust for United States Cellular Corporation

Via official filing (AI summary) | 11 days ago | 0 comments

259
1
DUOS TECHNOLOGIES GROUP, INC. Duos Technologies Reports $7.28 Million Revenue for Fiscal Year 2024, Faces 3% Decline

Via official filing (AI summary) | 11 days ago | 0 comments

260
1
Expion360 Inc. Expion360 Reports 6% Decrease in Net Sales for Fiscal Year 2024, Despite Q4 Revenue Surge

Via official filing (AI summary) | 11 days ago | 0 comments

261
1
Velo3D, Inc. Velo3D Reports 47% Revenue Decline and $73.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | 11 days ago | 0 comments

262
1
Bluejay Diagnostics, Inc. Bluejay Diagnostics Reports $7.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | 11 days ago | 0 comments

263
1
Biomea Fusion, Inc. Biomea Fusion Reports $138.4 Million Net Loss for 2024, Announces Leadership Transition and Strategic Shift

Via official filing (AI summary) | 11 days ago | 0 comments

264
1
Soluna Holdings, Inc Soluna Holdings Reports $63.3M Net Loss and Revenue Growth to $38M in 2024

Via official filing (AI summary) | 11 days ago | 0 comments

265
1
Dragonfly Energy Holdings Corp. Dragonfly Energy Reports 21.3% Revenue Decline, Faces Financial Challenges

Via official filing (AI summary) | 11 days ago | 0 comments

266
1
Mitesco, Inc. Mitesco, Inc. Reports $43,700 Revenue for Fiscal Year 2024, Significant Increase from Previous Year

Via official filing (AI summary) | 11 days ago | 0 comments

267
1
Vivos Therapeutics, Inc. Vivos Therapeutics Reports $15M Revenue for Fiscal Year 2024, Shifts Business Model

Via official filing (AI summary) | 11 days ago | 0 comments

268
1
Invizyne Technologies Inc eXoZymes Reports Improved Working Capital and Increased Net Loss in 2024

Via official filing (AI summary) | 11 days ago | 0 comments

269
1
CHINA PHARMA HOLDINGS, INC. China Pharma Holdings Reports 36% Revenue Decline and Gross Loss for Fiscal Year 2024

Via official filing (AI summary) | 11 days ago | 0 comments

270
1
Alaunos Therapeutics, Inc. Alaunos Therapeutics Reports $4.7 Million Net Loss for Fiscal Year 2024, Focuses on Obesity Program

Via official filing (AI summary) | 11 days ago | 0 comments

271
1
Orchestra BioMed Holdings, Inc. Orchestra BioMed Reports $61M Net Loss and 4% Revenue Decline for 2024

Via official filing (AI summary) | 11 days ago | 0 comments

272
1
Allarity Therapeutics, Inc. Allarity Therapeutics Reports $24.5 Million Net Loss and Strategic Focus on Stenoparib

Via official filing (AI summary) | 11 days ago | 0 comments

273
1
IO Biotech, Inc. IO Biotech Reports $95.5 Million Net Loss for 2024, Highlights Clinical Trial Progress

Via official filing (AI summary) | 11 days ago | 0 comments

274
1
AVENUE THERAPEUTICS, INC. Avenue Therapeutics Reports $11.7 Million Net Loss for 2024, Cash Reserves Increase

Via official filing (AI summary) | 11 days ago | 0 comments

275
1
HealthLynked Corp HealthLynked Corp. Reports 47% Revenue Decline and $6.1 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | 11 days ago | 0 comments